Over 5 Million Novavax COVID-19 Vaccines Produced in India

ANI News posted a video that revealed Serum Institute of India's (SII) CEO Adar Poonawalla informed the local media that the institute recently produced 5-6 million doses of the protein-based CovoVax™ COVID-19 vaccine.

However, as of April 22, 2023, the demand for CovoVax vaccines is zero in Indian hospitals.

Poonawalla added, "Current (SARS-CoV-2) variants are mild and not severe... However, senior citizens can take booster doses as a precaution."

These vaccines may be needed as the WHO South-East Asia Region, which includes India, recently reported a (+654%) increase in COVID-19 cases and fatalities.

Maryland-based Novavax, Inc. and SII confirmed CovoVax vaccine was authorized in Indonesia on December 1, 2021, and in India on December 28, 2021.

In the U.S., the U.S. FDA confirmed on August 19, 2022, that the Novavax COVID-19 Vaccine was available to prevent COVID-19 in individuals 12 years of age and older. 

Novavax COVID-19 vaccine brands are available in over 40 countries as of April 2023.